Dr. Ran Reshef, MD

Dr. Reshef practices at Columbia University Irving Medical Center in New York, New York.

Dr. Reshef's NPI, 1568659431, was assigned on September 25, 2007. Dr. Reshef graduated from Tel Aviv University Sackler in 1998. Dr. Reshef holds New York license 278144.

Dr. Reshef's primary practice is Columbia University Irving Medical Center, at 622 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 297-4255.

Dr. Reshef's primary practice is Columbia University Irving Medical Center in New York, New York. Dr. Reshef is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Reshef to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Reshef practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Reshef's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dmand AI has Dr. Reshef's licenses on file in 2 states: New York and Pennsylvania.

Dmand AI lists immune deficiency disease, multiple myeloma and purpura and thrombocytopenia among the conditions Dr. Reshef treats.

CMS data shows 442 Medicare services from Dr. Reshef across 5 procedure codes in 2024, for 55 Medicare patients. Medicare paid $41,544 for them.

CMS counts 55 Medicare patients who saw Dr. Reshef in 2024. The largest group is 65 to 74, with 27 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 31% are also on Medicaid. Their average risk score is 4.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Reshef's median patient age at 68, with 44% women.

In 2024, Dr. Reshef wrote 23 Medicare Part D claims. 65% of them were for generic drugs. CMS names the drug for 18 of them, across 1 drug with 11 or more claims each, at $59 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Reshef for performance year 2024, reported through an alternative payment model (APM). Dr. Reshef accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Reshef as offering telehealth.

Dmand AI links 116 papers to Dr. Reshef, published from 2006 to 2025. 2021 was the busiest year, with 12. The most frequent topics are Hematopoietic Stem Cell Transplantation, Graft vs Host Disease and Transplantation, Homologous. Dr. Reshef has published most often in Biol Blood Marrow Transplant. Dr. Reshef's most frequent co-authors are Elizabeth O. Hexner, MD, Alison W. Loren, MD and William J. Hogan, MBCHB.

Dmand AI links Dr. Reshef to 2 clinical trials, 2 of them phase 2 studies. Conditions studied include Anemia, Refractory, with Excess of Blasts, Hematologic Neoplasms and Anemia, Refractory.

CMS Open Payments shows 530 general payments to Dr. Reshef from 27 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 61% of the total. Kite Pharma, Inc. paid the most, $471,045. It also lists 1 research payment totaling $109 in 2019.

Dr. Reshef graduated from Tel Aviv University Sackler in 1998. Dr. Reshef is a member of ASCO.

Dr. Reshef is in network with 11 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.